Cannabix Technologies Develops Version 4.0 of THC Breath Analyzer Device
February 01 2022 - 8:45AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2022/1/31/Aspose.Words.df43e608-3cc8-43ab-a827-d6b1fdcd3a5e.001.png)
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
February 1, 2022 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of marijuana breathalyzer devices for law enforcement and
the workplace is pleased to report that it has assembled its
version 4.0 THC Breath Analyzer ("THCBA") prototype and portable
system for field use. This updated device incorporates planned
design changes and feedback from beta-test users. Several
components such as the device's internal sampling chambers,
microfluidic sensors and related actuation mechanism have been
changed to minimize manufacturing variability and to reduce cost.
Initial user testing has commenced and additional devices are being
assembled in preparation of delivery to existing and new beta-test
sites. Broader field testing and clinical testing to establish V4.0
benchmark standards are planned with this new device. A new image
of the THCBA version 4.0 is included in this press
release.
![](https://investorshub.advfn.com/uimage/uploads/2022/1/31/Aspose.Words.df43e608-3cc8-43ab-a827-d6b1fdcd3a5e.002.jpeg)
The THCBA is a drug screening
device for various markets who are seeking a way to quickly (in
less than 5 minutes), easily and non-invasively test for recent use
of ?9-tetrahydrocannabinol ("THC") - the psychoactive component of
marijuana that causes impairment. The THCBA consists of a handheld
device and protective case which houses a sterilization module,
sample preparation stage, device recovery station and integrated
battery charging system.
The THCBA system is geared to be a
cost effective, drug screening tool for employers and other markets
who are seeking a way to quickly, easily and non-invasively test
for recent use of THC. Employers everywhere are struggling with the
limitations of current drug testing technology in identifying
recent use of marijuana that may be causing impairment during work
hours and differentiating this from recreational and medical use
during nonwork hours/days. The Cannabix device allows for more
relevant THC detection from breath allowing employers to create an
onsite regiment whereby they can perform pre-access testing for
recent use of marijuana before and during work hours, instead of
testing for drug use when employees are not at work.
Breath testing for THC is a fairer and more
relevant test
Current forms of testing for marijuana use can
identify THC ranging from minutes to days after actual use, making
it impossible to show the difference between the two.
Studies¹ have shown that breath is
a better indicator of impairment than saliva, blood, or urine
because THC is present in breath for a relatively short period of
time (1-3 hours) after consumption; whereas, it is excreted at
detectable levels in other body fluids for many hours, days, or
even weeks after smoking. This short time period of detection in
breath aligns with the peak impairment window.
(1) Olla P, Ishraque
MT, Bartol S. 2020. Evaluation of Breath and Plasma
Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in
Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S. et al. 2013.
Cannabinoids in Exhaled Breath following Controlled Administration
of Smoked Cannabis. Clinical Chemistry; 1780-1789.
Beck O, Sandqvist S,
Dubbelboer I, Franck J. 2011. Detection of
delta9-tetrahydrocannabinol in exhaled breath collected from
cannabis users. J Anal Toxicol; 35:541- 4.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2023 to Aug 2024